VNRX-5133-103: A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics of VNRX-5133 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Cefepime/taniborbactam (Primary) ; VNRX-5022 (Primary)
- Indications Bacteroides infections
- Focus Pharmacokinetics
- Sponsors VenatoRx Pharmaceuticals
- 17 Oct 2018 Status changed from active, no longer recruiting to completed.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 11 Jan 2018 Status changed from recruiting to active, no longer recruiting.